SBI BIOTECH CO., LTD.
|SBI BIOTECH CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20140127223||ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE SIGMA ANTIBODY - A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase σ (human PTPRS), or a fragment including an antigen-binding region thereof.||05-08-2014|
|20140018533||NOVEL FURANONE DERIVATIVE - To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I):||01-16-2014|
|20130336967||ANTI-BST2 ANTIBODY - BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.||12-19-2013|
|20120135989||AZAINDOLE DERIVATIVE - The present invention provides a (di)azaindole derivative represented by the formula (I). A compound of the present invention inhibits a Cdc7 protein kinase activity and suppresses cell proliferation.||05-31-2012|
|20110190299||THIAZOLIDINONE DERIVATIVE - An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action.||08-04-2011|
Patent applications by SBI BIOTECH CO., LTD.